Login to Your Account


Mannkind optimistic on Afrezza program despite skeptics

By Jennifer Boggs
Managing Editor

Wednesday, January 15, 2014
SAN FRANCISCO – News of the tentative April 1 advisory committee to discuss Mannkind Corp.’s resubmitted new drug application for inhaled insulin Afrezza (insulin human [rDNA origin]) powder sent the Valencia, Calif.-based firm’s shares falling 16 percent last week.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription